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Historically, the surgical therapy of breast cancer was not
individualized. The radical mastectomy was developed at a
time when most cancers were locally advanced, and a large
operation was necessary for complete extirpation, but the
procedure was used for the treatment of small cancers as
well. The radical mastectomy was replaced by the modified
radical mastectomy, but again this procedure was applied to
all stages of disease.
During the past decade, substantial strides have been made
in the application of personalized surgical therapy, with the
majority of women now being offered a choice between
mastectomy alone, mastectomy with immediate recon-
struction, or breast-conserving therapy (BCT), consisting of
lumpectomy and radiation. Multiple prospective randomized
trials have shown no difference in survival between patients
treated with BCT and those undergoing mastectomy, even
after long-term follow up. Selection criteria for BCT have
been defined [1] and are related to the extent of disease
within the breast and the ability to administer radiotherapy
safely. Contraindications to BCT are as follows: first and
second trimester of pregnancy; inability to achieve negative
margins of resection; multicentric cancer; diffuse suspicious
or indeterminate microcalcifications; and history of prior
irradiation to breast region. Interestingly, biological factors such
as hormone receptor status, HER2 over-expression, tumour
grade and other histological features, and node status are not
useful criteria for identifying women best treated by mas-
tectomy. Adhering to the BCT contraindications given above,
local control rates of greater than 90% at 10 years are now
obtained in patients receiving adjuvant systemic therapy [2].
The use of gene profiles to predict the risk for systemic
recurrence [3] has raised interest in the role of these profiles
in identifying patients at high risk for local recurrence when
treated with BCT. Mamounas and coworkers [4] examined
the ability of the 21-gene recurrence score (Oncotype Dx™;
Genomic Health Inc., Redwood City, CA, USA) to identify
groups of women with different risks for locoregional
recurrence (LRR). The 21-gene recurrence score has been
shown to be both prognostic and predictive of the benefit of
adding chemotherapy to tamoxifen. In a retrospective study
using material from National Surgical Adjuvant Breast and
Bowel Project (NSABP) treatment trials, statistically
significant differences in LRR between women with low and
high risk scores were observed for those receiving no
systemic therapy, those treated with tamoxifen alone, and
those receiving both tamoxifen and chemotherapy. However,
the 10-year risk for LRR ranged from 1.6% in low-risk women
receiving chemotherapy and tamoxifen to 10.8% in those
receiving placebo, whereas the LRR rate in women with high
risk scores in these groups ranged from 7.8% to 18.4%,
respectively. It is unclear from this initial report whether a high
risk score is indicative of the need for more aggressive local
therapy or is an indication for more systemic therapy. In addition,
the clinical applicability of these findings is unclear because
decisions about local therapy must usually be made before one
knows what systemic therapy the patient will require. A
preliminary study from The Netherlands Cancer Institute [5],
conducted in a heterogeneous group of patients, suggested
that the wound response gene profile may identify patients at
high risk for LRR, but validation of this study is needed.
With the very high rates of local control obtained in women
treated with lumpectomy, breast irradiation, and systemic
therapy, it is unclear how valuable gene profiles will be in
further individualizing therapy within this model. However,
identification of patients who do not require radiotherapy
remains a major area of clinical interest. Multiple clinical trials
using conventional pathological and prognostic factors have
failed to identify a subgroup of women who do not achieve
some benefit from radiotherapy. Elimination of radiotherapy is
a particular concern because The Oxford Overview Analysis
[6] has demonstrated a statistically significant improvement in
breast cancer specific survival at 15 years for women who
received radiotherapy after lumpectomy compared with those
who did not. However, the time, expense, and potential
toxicity of radiotherapy remains a major drawback to BCT for
many women, and the identification of a subset of women at
low risk for local recurrence after lumpectomy alone would be
a major advance in further individualizing breast cancer
surgery.
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Sentinel node biopsy also represents a major step forward in
the individualization of surgical therapy. It is now clear that
sentinel node biopsy identifies axillary nodal metastases at
the same rate as axillary dissection, allowing dissection to be
limited to women with nodal disease who will benefit from the
procedure. The morbidity of sentinel node biopsy, both in the
immediate postoperative period and at 2 years, is significantly
less than that of axillary dissection.
In addition to these benefits, which have already been
observed, the more focused pathologic examination performed
on the sentinel node has resulted in increased detection of very
small tumour deposits. The prognostic significance of these
deposits remains a matter of debate, but their detection may
ultimately improve our ability to select local therapy for the axilla
and to quantify the risk for systemic relapse.
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